Markus Cornberg Selected Research

Alanine Transaminase (SGPT)

4/2023	Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
1/2022	Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.
1/2020	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs.
10/2016	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up.
2/2016	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Markus Cornberg Research Topics

Disease

96	Infections 03/2024 - 02/2002
41	Chronic Hepatitis C 04/2024 - 02/2002
39	Hepatitis C 03/2023 - 07/2004
36	Fibrosis (Cirrhosis) 03/2024 - 01/2014
26	Chronic Hepatitis B 03/2024 - 04/2010
24	Hepatitis B 02/2024 - 04/2010
19	Virus Diseases (Viral Diseases) 04/2024 - 02/2002
17	Liver Diseases (Liver Disease) 03/2024 - 01/2010
14	Chronic Hepatitis (Chronic Active Hepatitis) 05/2024 - 01/2010
14	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 05/2012
13	Hepatitis D 10/2023 - 03/2009
13	Hepatitis 09/2023 - 01/2010
12	Ascites 12/2023 - 01/2017
11	Liver Cirrhosis (Hepatic Cirrhosis) 02/2024 - 01/2010
11	COVID-19 02/2023 - 06/2020
8	Neoplasms (Cancer) 10/2022 - 01/2017
7	Coinfection 02/2024 - 01/2012
6	Chronic Hepatitis D 03/2024 - 01/2023
6	Persistent Infection 03/2024 - 02/2006
6	Disease Progression 10/2023 - 10/2008
4	Portal Hypertension 03/2024 - 01/2021
4	Non-alcoholic Fatty Liver Disease 05/2023 - 12/2016
4	Inflammation (Inflammations) 01/2022 - 01/2010
3	Hemorrhage 12/2023 - 01/2017
3	End Stage Liver Disease 04/2023 - 12/2020
3	Acute Kidney Injury (Acute Renal Failure) 10/2022 - 01/2018
3	Cross Infection (Nosocomial Infection) 01/2022 - 01/2020
2	Brain Diseases (Brain Disorder) 12/2023 - 01/2017
2	Hepatitis E 12/2023 - 01/2020
2	Peritonitis 01/2022 - 01/2018
2	Acute-On-Chronic Liver Failure 01/2022 - 01/2021
2	Convalescence 01/2022 - 01/2021
2	Lymphopenia (Lymphocytopenia) 12/2021 - 01/2021
2	Viremia 01/2021 - 01/2010
2	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2019
2	Hepatitis A (Hepatitis, Infectious) 08/2017 - 12/2006
2	HIV Infections (HIV Infection) 12/2012 - 11/2011

Drug/Important Bio-Agent (IBA)

56	Antiviral Agents (Antivirals)IBA 03/2024 - 12/2002
31	InterferonsIBA 03/2024 - 02/2002
31	RNA (Ribonucleic Acid)IBA 07/2023 - 12/2006
29	Hepatitis B Surface Antigens (HBsAg)FDA Link 04/2024 - 04/2010
21	Ribavirin (Virazole)FDA LinkGeneric 03/2024 - 02/2002
19	AntigensIBA 02/2024 - 06/2006
18	Hepatitis B e AntigensIBA 04/2024 - 04/2010
17	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 12/2009
16	Interferon-alpha (Interferon Alfa)IBA 01/2023 - 02/2002
12	Biomarkers (Surrogate Marker)IBA 11/2022 - 11/2011
12	CytokinesIBA 01/2022 - 10/2011
9	VaccinesIBA 02/2024 - 08/2015
9	Peptides (Polypeptides)IBA 10/2019 - 09/2007
8	EpitopesIBA 05/2023 - 01/2007
7	SofosbuvirIBA 03/2024 - 05/2013
7	BilirubinIBA 01/2020 - 08/2014
6	bulevirtideIBA 05/2024 - 01/2023
6	Tenofovir (Viread)FDA Link 10/2023 - 01/2019
6	Proteins (Proteins, Gene)FDA Link 05/2023 - 10/2004
6	AntibodiesIBA 01/2022 - 01/2010
5	Alanine Transaminase (SGPT)IBA 04/2023 - 02/2016
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2022 - 12/2005
5	peginterferon alfa-2a (Pegasys)FDA Link 01/2020 - 10/2015
4	AlbuminsIBA 07/2023 - 08/2014
4	Immunoglobulin G (IgG)IBA 01/2022 - 01/2010
4	glecaprevir and pibrentasvirIBA 01/2022 - 01/2020
3	Interleukin-10 (Interleukin 10)IBA 01/2021 - 10/2002
3	InterleukinsIBA 01/2021 - 10/2011
3	COVID-19 VaccinesIBA 01/2021 - 01/2021
3	ChemokinesIBA 01/2021 - 12/2016
3	LigandsIBA 01/2021 - 05/2010
3	Protease Inhibitors (Protease Inhibitor)IBA 07/2015 - 01/2013
3	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 08/2014 - 02/2012
2	nasIBA 03/2024 - 01/2023
2	HLA Antigens (Human Leukocyte Antigens)IBA 11/2022 - 01/2019
2	Meropenem (Merrem)FDA LinkGeneric 01/2022 - 07/2021
2	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2022 - 01/2020
2	EnzymesIBA 01/2022 - 05/2016
2	Blood Proteins (Serum Proteins)IBA 12/2021 - 12/2016
2	Lymphotoxin-alpha (Lymphotoxin)IBA 01/2021 - 11/2009
2	Interleukin-17 (Interleukin 17)IBA 01/2021 - 10/2019
2	Proton Pump InhibitorsIBA 08/2019 - 01/2018
2	Messenger RNA (mRNA)IBA 01/2019 - 10/2004
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2016 - 05/2010
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 11/2015 - 01/2012
2	telaprevirIBA 08/2014 - 01/2013
2	Immunoglobulin M (IgM)IBA 01/2014 - 12/2006
2	peginterferon alfa-2b (Pegintron)FDA Link 06/2013 - 09/2011
2	Natural Killer Cell ReceptorsIBA 05/2012 - 11/2011
2	Interferon alpha-2 (Roferon-A)FDA Link 07/2004 - 12/2002
1	Glycoproteins (Glycoprotein)IBA 04/2024

Therapy/Procedure

72	Therapeutics 04/2024 - 12/2002
17	Liver Transplantation 12/2023 - 10/2006
4	Transplantation 01/2021 - 01/2010
4	Immunotherapy 01/2020 - 05/2011
3	Retreatment 08/2023 - 01/2017
3	Contraindications 07/2023 - 01/2022
3	Surgical Portasystemic Shunt (Portosystemic Shunt) 07/2023 - 01/2020
3	Transjugular Intrahepatic Portasystemic Shunt 01/2022 - 01/2021
3	Aftercare (After-Treatment) 01/2021 - 01/2018
3	Duration of Therapy 01/2020 - 10/2006
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2018
2	Investigational Therapies (Experimental Therapy) 01/2020 - 11/2019